









Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on September 2023

Classification of products:

| Status | Description |
|---|--|
|  GREEN | Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies |
|  AMB 1 | Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline. |
|  AMB 2 | Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing. |
|  AMB SCP | AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only). |
|  RED | Red-Hospital initiation and continuation only |
|  GREY | GREY- NON FORMULARY (As agreed by Area Prescribing Committee) |
|  PURPLE | To be supplied from the appropriate commissioned provider. |
|  NR | Not routinely commissioned |

| Product | Decision | | | Comments/notes |
|--|----------|---------|----------|----------------|
| | Approved | Refused | Deferred | |
| 1) Requests deferred from previous meetings | | | | |
| Nil this month | | | | |
| 2) New Requests | | | | |
| Nil this month | | | | |
| 3) New formulations & extensions to use | | | | |
| Nil this month | | | | |

| Product | Decision | | | Comments/notes |
|--|----------|---------|----------|---|
| | Approved | Refused | Deferred | |
| 4) Products considered by NICE | | | | |
| TA906: Rimegepant for preventing migraine | AMB 2 | | | The formulary will reflect the TAG – ICS is the responsible commissioner |
| TA908: Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy | RED | | | The formulary will reflect the TAG – NHS England is the responsible commissioner. |
| TA909: Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer | RED | | | The formulary will reflect the TAG – NHS England is the responsible commissioner. |
| TA910: Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) | GREY | | | The formulary will reflect the TAG – ICS is the responsible commissioner |
| TA911: Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer | RED | | | The formulary will reflect the TAG – NHS England is the responsible commissioner. |
| 5) Appeals against earlier decisions by the APC | | | | |
| None | | | | |
| 6) Miscellaneous formulary decisions by the APC | | | | |
| Nil this month | | | | |

The following guidelines were presented to and approved at the September 2023 meeting of the APC:

- HNY Adult Asthma Guideline
- HNY Asthma Treatment 6-11 years guideline
- HNY Asthma Treatment 12-17 years guideline

The following Drug information leaflets were presented to and approved at the September 2023 meeting of the APC: Nil

The following shared care guidelines were presented to and approved at the September 2023 meeting of the APC: Nil

Other documents presented to and approved at the September 2023 meeting of the APC:

- Blood Glucose Meter Formulary